Minimal change glomerulopathy in a cat

Journal of Feline Medicine and Surgery

Volumn 13, Issue 4, 2011, Pages 291-295

  Backlund, Brianna ^a   Cianciolo, Rachel E ^b   Cook, Audrey K ^a   Clubb, Fred J ^a   Lees, George E ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CASE REPORT; CAT; CAT DISEASE; DRUG ANTAGONISM; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE COUNT; LIPOID NEPHROSIS; MALE;

ANIMALS; CAT DISEASES; CATS; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE COUNT; MALE; NEPHROSIS, LIPOID; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 79952607190     PISSN: 1098612X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfms.2010.12.011     Document Type: Article

References (14)

1. Lai K.W., Wei C.L., Tan L.K., et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 2007, 18:1476-1485.
2. Sum S.O., Hensel P., Rios L., et al. Drug-induced minimal change nephropathy in a dog. J Vet Intern Med 2010, 24:431-435.
3. Peng B., Lloyd P., Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005, 44:879-894.
4. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. N Engl J Med 2001, 344:1038-1042.
5. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052-1056.
6. Roufosse F., Goldman M., Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2007, 2:37.
7. Katayama R., Huelsmeyer M.K., Marr A.K., Kurzman I.D., Thamm D.H., Vail D.M. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 2004, 54:25-33.
8. Lachowicz J.L., Post G.S., Brodsky E. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. J Vet Intern Med 2005, 19:860-864.
9. Hahn K.A., Oglivie G., Rusk T., et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008, 22:1301-1309.
10. Alpers C.E., Seifert R.A., Hudkins K.L., Johnson R.J., Bowen-Pope D.F. PDGF-receptor localices to mesangial, parietal epithelial, and interstitial cells in human and primate kidneys. Kidney Int 1993, 43:286-294.
11. Daigle J., Moussy A., Mansfield C.D., Hermine O. Masitinib for the treatment of canine atopic dermatiits: a pilot study. Vet Res Comm 2010, 34:51-63.
12. Waters C.B., Adams L.G., Scott-Moncrieff J.C., et al. Effects of glucocorticoid therapy on urine protein-to-creatinine ratios and renal morphology in dogs. J Vet Intern Med 1997, 11:172-177.
13. Gillman P.K. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 2006, 59:1046-1051.
14. Gillman P.K. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol Clin Exp 2006, 21:117-125.